How Much Does Actos (Pioglitazone) Cost in Vermont in 2026?

Generic Pioglitazone Prices at Vermont Pharmacies

The most common way Vermonters fill pioglitazone is through a generic prescription at a retail pharmacy. Average cash-pay cost across the state sits near $15 per month for a 30-day supply of 30 mg tablets in 2026. That figure reflects pricing from chains like CVS, Walgreens, Rite Aid, and independent pharmacies operating in Burlington, Montpelier, Rutland, and smaller Vermont communities.

Generic pioglitazone has been available in the United States since 2012, when Takeda's patent on brand-name Actos expired. Multiple manufacturers now produce the drug, which has driven retail prices well below the original branded cost. Pharmacy pricing still varies. A shopper comparing two Burlington pharmacies might see quotes ranging from $8 to $22 for the same 30-tablet supply. GoodRx, RxSaver, and similar coupon aggregators often list pioglitazone 30 mg at $4 to $12 at participating Vermont locations. Pioglitazone consistently ranks among the least expensive oral diabetes medications on the market.

The FDA-approved prescribing information for Actos lists three tablet strengths: 15 mg, 30 mg, and 45 mg. Price differences between strengths are usually minimal for generics, though 45 mg tablets can cost a few dollars more per month at certain pharmacies. Patients prescribed 15 mg sometimes find that tablet-splitting a 30 mg pill, when scored, reduces cost further. Ask your pharmacist whether the specific manufacturer's tablet is appropriate for splitting.

Brand-Name Actos: Is It Worth the Extra Cost?

Brand-name Actos from Takeda lists at approximately $60 per month in 2026. That is four times the average generic price. The active ingredient is identical.

There is no clinical difference between generic pioglitazone and brand-name Actos. The FDA requires bioequivalence testing for all approved generics, meaning the generic version must deliver the same amount of drug into the bloodstream at the same rate. For a molecule like pioglitazone, an immediate-release oral tablet with high bioavailability, switching between manufacturers is straightforward. Vermont pharmacists may dispense any AB-rated generic unless the prescriber writes "dispense as written," a scenario that is rare for this drug class.

Some patients ask about Actos specifically because their insurance formulary lists it by brand name. In practice, pharmacy benefit managers almost always substitute the generic at point of sale. If your pharmacy is billing Actos at $60 and a generic alternative exists for $15, request the substitution directly.

Vermont Medicaid Coverage for Pioglitazone

Vermont Medicaid covers pioglitazone with prior authorization. The prior authorization requirement means the prescribing clinician must document medical necessity before Medicaid approves coverage.

Vermont's Medicaid preferred drug list, maintained by the Department of Vermont Health Access (DVHA), categorizes thiazolidinediones as a covered class with conditions. The PA process typically requires documentation that the patient has tried or cannot tolerate metformin, which remains the first-line agent per American Diabetes Association Standards of Care. Once PA is granted, the copay for generic pioglitazone under Vermont Medicaid is usually $1 to $3 per fill, depending on the beneficiary's income tier.

Green Mountain Care, Vermont's Medicaid expansion program, follows the same formulary. Beneficiaries enrolled through the Vermont Health Connect marketplace who receive Medicaid-equivalent coverage also have access to pioglitazone under the PA pathway. Processing time for prior authorization requests averages 24 to 72 hours in Vermont, though urgent requests can be expedited within 24 hours by the prescriber calling the DVHA pharmacy line.

Pioglitazone has a secondary off-label use in nonalcoholic steatohepatitis (NASH). The PIVENS trial (N=247) published in the New England Journal of Medicine demonstrated that pioglitazone 30 mg daily improved histological features of NASH in patients without diabetes. Vermont Medicaid may not cover pioglitazone for this off-label indication without additional clinical documentation. Prescribers seeking coverage for NASH-related use should include liver biopsy results or imaging findings and reference current hepatology guidelines in the PA request.

Private Insurance and Pioglitazone in Vermont

Most commercial insurers operating in Vermont place generic pioglitazone on Tier 1 or Tier 2 of their formularies. That translates to copays between $0 and $20 per month for the majority of plan members.

Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna all list pioglitazone as a covered generic. Tier 1 placement, the lowest copay tier, is common because pioglitazone is inexpensive for insurers to reimburse. Patients with high-deductible health plans (HDHPs) may pay the full cash price until their deductible is met, but at $15 per month, pioglitazone rarely creates significant out-of-pocket burden even in that scenario.

Employer-sponsored plans in Vermont follow similar patterns. According to the Kaiser Family Foundation's 2024 Employer Health Benefits Survey, the average Tier 1 copay nationally was $11 for generic drugs. Vermont's commercial market tracks closely with that national benchmark. Large employers headquartered in Vermont, including GlobalFoundries and the University of Vermont Health Network, typically offer pharmacy benefits that cover pioglitazone without prior authorization, unlike Medicaid.

If your insurer requires step therapy (trying metformin first), your prescriber can submit a step-therapy exception if you have a documented contraindication. Lactic acidosis risk with metformin in patients with renal impairment (eGFR <30 mL/min/1.73 m²) or active heart failure is the most common clinical basis for an exception. The FDA label for metformin details these contraindications.

Compounded Pioglitazone in Vermont

Compounded pioglitazone is legal and available in Vermont through licensed 503A pharmacies. These pharmacies can prepare custom formulations when a patient has a documented need that commercially manufactured tablets do not meet.

Common reasons for compounding pioglitazone include dysphagia (difficulty swallowing tablets), allergy to an inactive ingredient in manufactured versions, or a need for a non-standard dose. Vermont's Board of Pharmacy regulates 503A compounding pharmacies under state and federal guidelines established by the Drug Quality and Security Act of 2013. A valid patient-specific prescription is required. Bulk compounding without individual prescriptions falls under 503B outsourcing facility rules, a separate regulatory category.

Pricing for compounded pioglitazone varies widely. Some 503A pharmacies in Vermont price compounded formulations competitively, while others charge a preparation fee that can exceed the cost of commercial generics. Because pioglitazone's active pharmaceutical ingredient (API) is inexpensive, the compounding cost is driven primarily by labor and overhead rather than raw materials. Patients considering compounded pioglitazone should compare the total cost against the $15 average for manufactured generics.

Insurance coverage for compounded medications is inconsistent. Vermont Medicaid generally does not cover compounded drugs unless the prescriber documents that no commercially available product meets the patient's medical need. Commercial insurers in Vermont follow similar policies. Patients who use compounded pioglitazone often pay out of pocket.

Telehealth Access to Pioglitazone in Vermont

Vermont permits telehealth prescribing of pioglitazone. State law allows clinicians to establish a patient-provider relationship via synchronous audio-video visit and prescribe non-controlled medications, including pioglitazone, without an in-person exam.

Vermont was among the first states to pass comprehensive telehealth parity legislation. Act 131 (2018) requires private insurers to cover telehealth services at the same rate as in-person visits. Vermont Medicaid also reimburses telehealth encounters for chronic disease management, including diabetes care. This means a Vermonter in the Northeast Kingdom, where endocrinology practices are scarce, can see a licensed prescriber via video and receive a pioglitazone prescription sent to their local pharmacy.

HealthRX and similar telehealth platforms can connect Vermont residents with clinicians experienced in metabolic health. The prescriber reviews labs (fasting glucose, HbA1c, liver enzymes, lipid panel), confirms the diagnosis, evaluates contraindications, and transmits the prescription electronically. Pioglitazone requires baseline and periodic ALT monitoring per the FDA label, so telehealth prescribers typically order labs through a local draw site before initiating therapy.

Patients with type 2 diabetes starting pioglitazone should expect an initial lab panel, a follow-up ALT check at 3 months, and periodic monitoring thereafter. The drug takes 8 to 12 weeks to reach full glycemic effect, so clinicians usually reassess HbA1c at the 3-month mark.

Discount Programs and Savings Cards

Several discount pathways can reduce pioglitazone cost below the $15 Vermont average. Manufacturer savings cards, pharmacy discount programs, and nonprofit patient assistance all apply.

Takeda's savings card for Actos is designed primarily for the brand-name product and has limited value when the generic already costs $15 or less. Generic manufacturers do not typically offer direct-to-patient savings cards. The more practical discount tools for Vermont patients are pharmacy-level programs. Walmart's $4 generic list, Costco's member pricing, and Mark Cuban's Cost Plus Drugs have all carried pioglitazone at prices between $4 and $8 per month. Cost Plus Drugs ships to Vermont addresses and charges a transparent markup over wholesale cost plus a flat pharmacy fee.

For uninsured Vermonters, the 340B Drug Pricing Program offers another avenue. Federally qualified health centers (FQHCs) in Vermont, including Community Health Centers of Burlington and Northern Counties Health Care, participate in 340B and can dispense pioglitazone at reduced prices. Eligibility is based on receiving care at a 340B-covered entity, not on income alone.

NeedyMeds and RxAssist maintain databases of patient assistance programs that include pioglitazone. Because the drug is inexpensive even at full cash price, assistance programs are less commonly needed than for high-cost specialty medications. Still, every dollar matters for patients managing multiple chronic conditions with several co-prescribed drugs.

Clinical Context: Why Pioglitazone Is Prescribed

Pioglitazone is a thiazolidinedione (TZD) that improves insulin sensitivity in muscle, adipose tissue, and the liver. The FDA approved it in 1999 for type 2 diabetes mellitus as monotherapy or in combination with metformin, sulfonylureas, or insulin.

The drug's clinical value extends beyond glucose lowering. In the PROactive trial (N=5,238), pioglitazone reduced the composite secondary endpoint of all-cause mortality, nonfatal myocardial infarction, and stroke by 16% (HR 0.84, P=0.027) over 34.5 months in patients with type 2 diabetes and macrovascular disease. The IRIS trial (N=3,876) published in the New England Journal of Medicine showed that pioglitazone reduced stroke and myocardial infarction risk by 24% in insulin-resistant patients without diabetes who had experienced a recent ischemic stroke.

For NASH, the PIVENS trial found that pioglitazone 30 mg daily for 96 weeks improved steatosis, inflammation, and ballooning on liver biopsy. Resolution of NASH occurred in 47% of pioglitazone-treated patients versus 21% on placebo (P=0.001). The American Association for the Study of Liver Diseases (AASLD) guidance lists pioglitazone as a pharmacotherapy option for biopsy-proven NASH, regardless of diabetes status.

Weight gain and fluid retention are the primary side effects. Average weight gain in clinical trials was 2 to 4 kg over 6 to 12 months. Pioglitazone is contraindicated in NYHA Class III or IV heart failure. The FDA issued a safety communication in 2016 noting a possible small increased risk of bladder cancer with prolonged use, though subsequent meta-analyses have yielded conflicting results.

How Vermont Compares to Other New England States

Pioglitazone pricing in Vermont is consistent with the broader New England market. Cash-pay generics range from $10 to $20 per month across Connecticut, Massachusetts, New Hampshire, Maine, and Rhode Island.

Vermont's relatively small pharmacy market means less price competition than in Massachusetts or Connecticut, where pharmacy density is higher. Independent pharmacies in rural Vermont may quote slightly above $15 for generics, while larger chains with centralized purchasing tend to price at or below the state average. Vermont does not impose a state-level prescription drug tax, which keeps retail prices marginally lower than in states with such levies.

Medicaid coverage terms vary by state. Massachusetts MassHealth covers pioglitazone without prior authorization on its preferred drug list, while Vermont requires PA. New Hampshire Medicaid also requires PA. These differences affect time-to-therapy for newly diagnosed patients but not long-term cost once authorization is secured.